EFFEKTIVNOST' KOMBINIROVANNOY ANTIGIPERTENZIVNOY TERAPII ZhENShchIN S ARTERIAL'NOY GIPERTENZIEY I IShEMIChESKOY BOLEZN'Yu SERDTsA, VKLYuChAYuShchEY RAZLIChNYE BLOKATORY RENIN-ANGIOTENZINOVOY SISTEMY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of the study involving 100 women with arterial hypertension (AH) and stable coronary heart disease (CAD); the study was aimed to the evaluation of antihypertensive efficacy of ACE inhibitor zofenopril and angiotensin II receptor blocker valsartan using once a day and twice a day administration. Follow-up period was 24 weeks. It has been shown that combined antihypertensive therapy based on administration of valsartan twice a day may have advantages over the use of zofenopril in women with a combination of arterial hypertension and stable coronary artery disease.

Full Text

Restricted Access

References

  1. Wyskida K., Jura-Szoltys E., Smertka M., et al. Factors that favor the occurrence of cough in patients treated with ramipril-a pharmacoepidemiological study. Med Sci Monit. 2012; 18(9): 21-8.
  2. Dahlof B, Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan intervention for Endpoint reduction in hypertension study (LiFE): A randomized trial against atenolol. Lancet. 2002; 359: 995-1003.
  3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5-26.
  4. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2008; 7(6). Приложение 4.
  5. Capri Workshop Group. Hormones and cardiovascular health in women. Human Report Update. 2006; 12: 483-97.
  6. Рекомендации по снижению общего риска развития заболеваний и осложнений у женщин. М., 2010.
  7. Reckelhoff J.F. Basic research into the mechanisms responsible for postmenopausal hypertension. int. J. Clin. Pract. 2004; 58(suppl. 139): 13-9.
  8. Dzan V., Sasamura H., Hein L. Heterogeneity of angiotensin synthetic pathways and subtypes: Physiological and pharmacological implication.J. Hypertension. 1993; 11: 13-8.
  9. Urata H., Boehm K.D., Philip A. et al. Cellular localization and regional dis-tribution of an angiotensin ii-forming chymase in the heart. J Clin invest. 1993; 91: 1269-81.
  10. Nishimura H., Hoffman S., Baltatu O. et al. Angiotensin i converting enzyme and chymase in cardiovascular tissues. Kidney int. 1996; 49: 18-23.
  11. Denton K.M., Hilliard L.M., Tare М. Sex-Related Differences in Hypertension: Seek and Ye Shall Find. Hypertension. 2013; 62: 674-77.
  12. Brown R.D., Hilliard L.M., Head G.A., et al. Sex differences in the pressor and tubuloglomerular feedback response to angiotensin ii. Hypertension. 2012; 59: 129-35.
  13. McCarthy C.A., Widdop R.E., Denton K.M., Jones E.S. Update on the angiotensin AT(2) receptor. Curr. Hypertens Rep. 2013; 15: 25-30.
  14. Скибицкий В.В., Медведева Ю.Н., Шухардина Е.Л. и др. Факторы риска и структура кардиоваскулярной патологии у женщин в климаксе различного генеза. Проблемы женского здоровья. 2007; 3(2): 21-8.
  15. Hermida R.C., Ayala D.E., Mojon A., et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing Chronobiol int. 2011; 28(7): 601-10.
  16. Yoshida H., Shimizu M., Ikewaki K. et al. Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study. J. Hypertens. 2010; 28(6): 1150-57.
  17. Mazzolai L., Daven V., Centeno C., Nussberger J., Brunner H.R., Burnier M. Assessment of angiotensin ii receptor blockade in humans using a standardized angiotensin ii receptor-binding assay. Am. J. Hypertens. 1999; 12(12 Pt1-2): 1201-08.
  18. Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. int J. Clin. Pract.2006; 60; 3: 315-20.
  19. Ando H., Ushijima K., Hosohata K., et al. Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. Br. J. Clin. Pharmacol. 2013; 75(2): 415-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies